B
Bull
Bull · 25%NYXH
$9.24
Scenario price
$1.600
+0.031 (+1.91%)At close
Loading chart…
- High
- 1.630
- Open
- 1.590
- VWAP
- 1.60
- Vol
- 86.03K
- Mkt Cap
- 236.06M
- Low
- 1.570
- Amount
- 137.65K
- EV/EBITDA, TTM
- -0.79
Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
AI analysis of Nyxoah SA (NYXH)
holdNyxoah SA is not a strong buy right now due to significant recent losses and mixed analyst ratings. The current price is $1.60, with a one-year change of -72.88%, indicating a steep decline. Although the company reported a 21% revenue growth in Q2 2026, the net income remains negative at -32,964,000 EUR for the same quarter, which raises concerns about profitability. The RSI is at 51.048, suggesting a neutral momentum, and the forward P/E ratio is not applicable due to negative earnings, indicating a lack of clear valuation metrics. The main risk is the high debt-to-equity ratio of 72.18%, which could impact financial stability.
Valuation Metrics
The current forward P/E ratio for Nyxoah SA (NYXH) is 0.00, compared to its 5-year average forward P/E of -4.69.
Alphio AI Price Scenarios for NYXH
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding NYXH
Events Timeline
News
8.508-25NewsfilterNyxoah Announces New Share Issuance Details
9.507-07seekingalphaNyxoah SA Reports 21% Revenue Growth in Q2 2026
- 8.506-30Newsfilter
Nyxoah SA Voting Rights and Share Information Released
- 7.006-29Newsfilter
Nyxoah Receives Transparency Notifications from Major Shareholders
- 1.006-19Newsfilter
Nyxoah Invites Shareholders to Extraordinary Meeting on July 9, 2026
NYXH FAQ — answered by Alphio AI
Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin. It operates in the Healthcare sector.
Nyxoah SA is not a strong buy right now due to significant recent losses and mixed analyst ratings. The current price is $1.60, with a one-year change of -72.88%, indicating a steep decline. Although the company reported a 21% revenue growth in Q2 2026, the net income remains negative at -32,964,000 EUR for the same quarter, which raises concerns about profitability. The RSI is at 51.048, suggesting a neutral momentum, and the forward P/E ratio is not applicable due to negative earnings, indicating a lack of clear valuation metrics. The main risk is the high debt-to-equity ratio of 72.18%, which could impact financial stability.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.